Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | HINT1 | P49773 | 3/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471689 | 1.00 | ADORA3 (0.59) | ADORA3HINT1STING1PDE3BPDE3A | |
| SCHEMBL14853765 | 1.00 | ADORA3 (0.59) | ADORA3HINT1STING1PDE3BPDE3A | |
| SCHEMBL14946268 | 1.00 | ADORA3 (0.59) | ADORA3HINT1STING1PDE3BPDE3A | |
| SCHEMBL3437123 | 1.00 | ADORA3 (0.59) | ADORA3HINT1STING1PDE3BPDE3A | |
| SCHEMBL22474911 | 0.92 | ADORA3 (0.55) | ADORA3HINT1STING1PDE3BPDE3A | |
| SCHEMBL22644423 | 0.92 | HINT1 (0.55) | ADORA3HINT1STING1PDE3BPDE3A | |
| SCHEMBL14948887 | 0.91 | ADORA3 (0.56) | ADORA3HINT1STING1PDE3BPDE3A | |
| SCHEMBL23520033 | 0.90 | ADORA3 (0.55) | ADORA3HINT1STING1PDE3BPDE3A | |
| SCHEMBL747893 | 0.90 | ADORA3 (0.55) | ADORA3HINT1STING1PDE3BPDE3A | |
| SCHEMBL747894 | 0.90 | ADORA3 (0.55) | ADORA3HINT1STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | claimed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4015005-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4015005-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3682905-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3682905-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2013052523-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-04-11 | — | — | WO | disclosed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ADORA3 95/4885HINT1 78/4885STING1 332/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ADORA3 95/4885HINT1 78/4885STING1 332/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | ADORA3 729/4885HINT1 308/4885STING1 1578/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | ADORA3 729/4885HINT1 308/4885STING1 1578/4885 |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | RNMT, RNGTT, NSUN2 | ADORA3 335/4885HINT1 362/4885STING1 358/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | ADORA3 729/4885HINT1 308/4885STING1 1578/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | ADORA3 729/4885HINT1 308/4885STING1 1578/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ADORA3 95/4885HINT1 78/4885STING1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.